Investigation of Soleno Therapeutics, Inc.
Recent developments have emerged regarding allegations against Soleno Therapeutics, Inc. (NASDAQ: SLNO). The law firm Edelson Lechtzin LLP is conducting an in-depth investigation centered on potential violations of federal securities laws.
Background on Soleno Therapeutics
Soleno Therapeutics is committed to developing groundbreaking treatments for rare diseases, particularly in the realm of genetic disorders. Their innovative approach highlights their dedication to addressing significant medical needs in patient populations that are often overlooked.
Recent Drug Authorizations
In March 2025, the FDA granted approval for Soleno's VYKAT™ XR (diazoxide choline). This medication aims to assist patients with Prader-Willi syndrome, a condition characterized by hyperphagia and associated challenges. The excitement surrounding the launch initially seemed promising, with the company reporting strong launch metrics.
The Allegations
However, a sudden announcement in November 2025 revealed an 8% discontinuation rate attributed to non-serious adverse events, which has raised concerns among investors. Additionally, a short-seller report released in August suggested that it had hindered the drug's rollout. As a result, the company's stock faced a dramatic decline, dropping over 26% in value within a single day.
How to Get Involved
If you have relevant information regarding the investigation or have experienced significant losses as a Soleno investor, Edelson Lechtzin LLP encourages you to reach out. Engaging in the process can provide crucial insights into the situation and assist in upholding the integrity of the financial markets.
About Edelson Lechtzin LLP
Edelson Lechtzin LLP operates as a national class action law firm with a focus on holding corporations accountable for security violations. Their team specializes in various litigation areas, including securities fraud and class actions concerning consumer protection and workplace rights.
Contact Information
For those seeking further information, you can connect with attorney Eric Lechtzin by calling 844-563-5550 or via email at elechtzin@edelson-law.com. You can also reach out to Marc H. Edelson at medelson@edelson-law.com.
Frequently Asked Questions
What is Edelson Lechtzin LLP investigating?
The firm is investigating potential violations related to misleading statements made by Soleno Therapeutics, impacting investors.
What happened with Soleno Therapeutics' VYKAT™ XR?
The launch was initially viewed positively but later encountered challenges leading to a significant drop in stock value after adverse events were reported.
How can I participate in the investigation?
Investors with relevant information or those affected may contact Edelson Lechtzin LLP for assistance in the investigation.
What are the potential legal implications for Soleno?
Should the allegations be substantiated, Soleno may face legal repercussions that could affect its operations and investor recoveries.
How can I get in touch with the law firm?
You can reach out directly by phone or email to the attorneys at Edelson Lechtzin LLP for more information about the situation.
